Search Results for “ diabetes” – Page 11 – media

AI+drug target discovery | Insitro and Eli Lilly reach strategic agreement to jointly promote new therapies for metabolic diseases

Zhiyao Bang October 23, 2024 09:01 Shanghai On October 9, 2024, insitro, a new drug development company that supports machine learning, announced the signing of three strategic agreements with Eli Lilly, focusing on developing potential new drugs for the treatment of metabolic diseases, including metabolic dysfunction associated fatty liver (MASLD), based on the targets identified by insitro using the company’s AI based platform.Metabolic diseases, including MASLD, affect millions of people worldwide, but effective treatment options are still limited. The current treatment mainly treats the symptoms rather than the root cause. This collaboration aims to combine Insitro’s machine learning platform with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology to change existing models. According to the first two agreements, Insitro can choose to license Lilly’s proprietary, clinically advanced ternary N-acetylglucosamine (GalNAc) delivery technology, which will be combined with two different small interfering RNA (siRNA) molecules discovered and developed by ...
- Source: drugdu
- 74
- October 24, 2024
75.4 billion! Abbott’s Q3 performance exceeded expectations

Yesterday (October 17th), Abbott announced its third quarter 2024 financial report on its official WeChat account. Abbott’s global sales in the third quarter reached 10.6 billion US dollars (approximately 75.48 billion yuan), with an organic growth of 8.2% and a reported sales growth of 4.9%. Based on the brilliant performance in this quarter, Abbott said that after excluding the impact of COVID-19 testing products, the company expects global sales to achieve an organic growth of 9.5% to 10.0% in 2024, and diluted earnings per share after adjustment for the whole year may be between 4.64 and 4.70 dollars, the median of the range is higher than the previous estimate. Continuous growth achieved through multiple business operations According to the financial report, Abbott’s multiple departments have achieved business growth. Among them, the medical device department achieved double-digit growth, with global sales reaching $4.7 billion in the third quarter, an organic growth ...
- Source: drugdu
- 74
- October 23, 2024
GLP-1 Can Improve Opioid Addiction Issues

A recent study indicates that Novo Nordisk’s Ozempic and similar GLP-1 medications may reduce patients’ misuse of opioids and alcohol, further demonstrating the broad potential of GLP-1 drugs beyond treating obesity and diabetes. This study was published on Thursday, October 17, in the journal *Addiction*. The research aims to further explore the growing potential uses of GLP-1 and seeks to address the troubling issue of opioid addiction among patients. An analysis conducted on 500,000 opioid-addicted patients revealed that those using GLP-1 medications had a 40% lower rate of opioid overdose compared to those who did not take GLP-1 medications. Additionally, similar comparative research was conducted among alcoholics. The results showed that among over 5,000 alcoholics using GLP-1 drugs, the rate of excessive drinking was 50% lower compared to those not using GLP-1. New Treatment Options The lead researcher, Dr. Fares Qeadan, an associate professor of biostatistics at Loyola University Chicago, ...
- Source: drugdu
- 70
- October 18, 2024
3.7 billion blockbuster antihypertensive drug, Shandong New Era approved for listing!

Yesterday (October 14), the official website of the National Medical Products Administration (NMPA) announced that the Sacubitril Valsartan Sodium Tablets submitted by Shandong New Era Pharmaceuticals were approved and passed the review. Sacubitril Valsartan Sodium Tablets is an antihypertensive drug used for adult patients with chronic heart failure with reduced ejection fraction. As the world’s first breakthrough innovative drug in the field of heart failure treatment, Sacubitril Valsartan Sodium Tablets entered the Chinese market in 2017 for the treatment of heart failure, and was later included in the 2020 National Medical Insurance Catalogue. In June 2021, it was first approved in China for the treatment of essential hypertension. In 2021, in-hospital sales exceeded 2 billion yuan in one fell swoop, a year-on-year increase of 170%. According to the Zhongkang Kaisi system, the sales of hypertension drugs in graded hospitals in 2023 will reach about 24.2 billion yuan. In the subdivided ...
- Source: drugdu
- 70
- October 17, 2024
Partners with 10 Indian AI Startups

Novo Nordisk recently partnered with 10 Indian artificial intelligence (AI) startups, marking an important moment for the Indian AI ecosystem. The Danish company, best known for its weight loss drug Wegovy, is leveraging AI innovations to streamline operations and improve efficiency. The moves are part of the Danish drugmaker’s expansion plans for operations in Bangalore, which it opened 17 years ago. The center helps manage the vast amounts of data collected about the safety and effectiveness of its drugs, including clinical trial information and reports of potential side effects. One of the factors driving the move is that demand for obesity and diabetes-related drugs is expected to grow, especially as global attention to these health issues grows. By strategically positioning itself in India, one of the world’s largest markets for diabetes drugs, Novo Nordisk expects to meet the growing demand by increasing its production capacity. The partnership also has a ...
- Source: drugdu
- 64
- October 17, 2024
Collaborating with 10 Indian AI startups

These measures are part of the business expansion plan launched by this Danish pharmaceutical company in Bangalore 17 years ago. The center helps manage a large amount of data collected regarding the safety and efficacy of its drugs, including clinical trial information and potential side effect reports. One of the factors driving this initiative is that the demand for obesity and diabetes related drugs is expected to grow, especially with the increasing global attention to these health problems. Through strategic positioning in India (one of the world’s largest diabetes drug markets), Novo Nordisk is expected to meet the growing demand by improving its production capacity. This partnership has also had a broader impact on the operations of Novo Nordisk. It is expected that Novo Nordisk’s Bangalore center will become an approximate mirror of its Danish headquarters within three years. The company plans to increase the number of employees in Bangalore ...
- Source: drugdu
- 62
- October 16, 2024
GCGR agonist rejected twice

Original Time Biopharmaceutical Editor October 14, 2024 09:20 Shanghai The weight loss drug concept stock Zealand has suffered another setback, as its new drug Dasiglucagon, which was launched to treat congenital hyperinsulinemia (CHI) in children, has once again been rejected by the FDA. Last December, Dasiglucagon was rejected by the FDA for the first time due to the discovery of defects in a third-party contract manufacturing factory. Zealand pointed out that the main reason for Dasiglucagon’s second rejection was that the FDA failed to complete the re inspection of third-party production factories, resulting in the approval process being put on hold. The FDA did not raise any concerns about the effectiveness or safety of Dasiglucagon. Dasiglucagon is a glucagon receptor (GCGR) agonist that acts to release stored glycogen from the liver into the bloodstream. Hypoglycemia is one of the most common acute complications of diabetes, and patients who have the ...
- Source: drugdu
- 62
- October 15, 2024
【EXPERT Q&A】Can metformin fight aging?

Drugdu.com expert’s response: Metformin, a widely used antidiabetic drug, has shown potential in recent research on anti-aging. Specifically, its anti-aging effects are manifested in the following aspects: Ⅰ. Scientific Research Achievements Research by the Chinese Academy of Sciences Team: After an extensive 8-year study, the team led by Liu Guanghui from the Institute of Zoology, Chinese Academy of Sciences, discovered that metformin can reset the intrinsic program of cellular aging, significantly delaying aging in primates. This achievement was published in the journal “Cell”, providing new insights into the biological mechanisms of aging and potential strategies for future interventions in human aging. Experimental Evidence: The research team conducted a 40-month follow-up study on middle-aged and elderly male crab-eating macaques. The results showed that individuals who took metformin long-term exhibited significant delays in aging, including reduced brain cortex atrophy, improved cognitive function, delayed periodontal bone degeneration, and protection of multiple tissues and ...
- Source: drugdu
- 71
- October 11, 2024
Seven domestic companies have completed a new round of financing, focusing on the fields of cell and gene therapy

In September, several domestic companies focused on the field of cell and gene therapy (CGT) announced progress in financing. This article will share basic information about its 7 companies based on publicly available materials. Xingsairui has successfully completed tens of millions of yuan in angel round financing On September 14th, Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (hereinafter referred to as “Xingsai Ruizhen”) announced the completion of tens of millions of yuan in angel round financing and officially launched the angel+round financing plan! This round of financing is jointly invested by Fosun Pharma’s Rehabilitation Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund. This round of financing will be used for the continuous promotion of core pipelines and platforms, as well as the construction of the company’s team and research and development laboratories. Xingsai Ruizhen was founded in July 2022 and incubated by the New Drug Innovation ...
- Source: drugdu
- 114
- October 3, 2024
The “No.1 Chinese hepatitis C drug” is looking for a new engine

Recently, Ascletis announced that its independently developed small molecule GLP-1R agonist ASC30 is undergoing two Phase I clinical trials in the United States for the treatment of obesity with monthly subcutaneous injections and daily oral tablets. With the launch of these two Phase I clinical trials, Ascletis has officially entered the field of weight loss drugs. This is another highlight of the pipeline after Ascletis announced in April this year that it would focus on the development of core non-alcoholic steatohepatitis (NASH) drugs. Urgent need for a new engine Like most biotechs, Ascletis has also been moving forward by trial and error. However, Ascletis is luckier than most biotechs. It has become famous for its first local original hepatitis C drug Ganovo, which not only broke the monopoly of multinational companies such as Gilead, AbbVie, Bristol-Myers Squibb, and Merck in the domestic hepatitis C drug market, ...
- Source: https://news.yaozh.com/archive/44305.html
- 75
- October 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.